Advisory Services Network LLC lowered its holdings in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 47.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,250 shares of the specialty pharmaceutical company’s stock after selling 5,550 shares during the period. Advisory Services Network LLC’s holdings in Collegium Pharmaceutical were worth $95,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in COLL. MERIAN GLOBAL INVESTORS UK Ltd acquired a new stake in shares of Collegium Pharmaceutical in the first quarter worth $26,000. First Quadrant L P CA acquired a new stake in shares of Collegium Pharmaceutical in the first quarter worth $36,000. BNP Paribas Arbitrage SA increased its position in shares of Collegium Pharmaceutical by 67,855.6% in the first quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock worth $93,000 after acquiring an additional 6,107 shares in the last quarter. Oregon Public Employees Retirement Fund acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth $103,000. Finally, Virginia Retirement Systems ET AL acquired a new stake in shares of Collegium Pharmaceutical in the first quarter worth $160,000. 94.83% of the stock is owned by institutional investors.
Shares of COLL stock traded down $0.31 on Thursday, hitting $10.53. The stock had a trading volume of 218,267 shares, compared to its average volume of 390,582. Collegium Pharmaceutical Inc has a 52-week low of $10.41 and a 52-week high of $21.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.24 and a quick ratio of 1.19. The stock has a market capitalization of $361.11 million, a price-to-earnings ratio of -8.85 and a beta of 0.55. The business has a 50 day simple moving average of $12.06.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $12.84, for a total value of $321,000.00. Following the transaction, the director now directly owns 188,586 shares in the company, valued at approximately $2,421,444.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Scott Dreyer sold 2,857 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $12.31, for a total transaction of $35,169.67. Following the completion of the transaction, the executive vice president now owns 40,596 shares in the company, valued at $499,736.76. The disclosure for this sale can be found here. Insiders have sold a total of 91,144 shares of company stock worth $1,075,506 over the last quarter. 8.08% of the stock is currently owned by insiders.
Several equities research analysts have recently issued reports on the stock. Janney Montgomery Scott assumed coverage on shares of PLx Pharma in a research report on Friday, April 12th. They issued a “buy” rating for the company. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. HC Wainwright reissued a “buy” rating on shares of Ballard Power Systems in a research report on Friday, May 3rd. Zacks Investment Research downgraded shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Cantor Fitzgerald set a $135.00 target price on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Friday, April 26th. Three investment analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $26.17.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Further Reading: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.